At a minimum, the practice of responsible medicine requires that physicians who prescribe drugs whose known severe adverse side effects are likely to cause their patients irreversible harm, requires that those physicians follow monitoring guidelines to ensure their patients’ safety.
Three new studies–one,, a pharmaco-genetic study, is groundbreaking–confirm that widely prescribed psychotropic drugs that pose serious risks of harm, offer no therapeutic benefit.
An audit by Daniel Levinson, Inspector General of DHHS, confirms what has already been documented: that antipsychotics are widely misprescribed for unapproved uses and taxpayers are saddled with the high cost through Medicaid and Medicare. Continue reading →
New FDA antipsychotic Warnings: "The symptoms of EPS and withdrawal in newborns may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty in feeding." Continue reading →
The excerpts from The New Yorker (below) may be read as a companion piece to the Atlantic article profiling Dr. John Ioannidis. However, the opening example that Lehrer uses to make the point that initial impressive positive research findings often weaken . . . Continue reading →
"Prescription Drugs Associated with Reports of Violence Towards Others, " identifies 31 drugs linked to 1,527 acts of violence… Continue reading →
"When you’re selling $1 billion a year or more of a drug, it’s very tempting for a company to just ignore the traffic ticket and keep speeding.” Continue reading →
According to a report by the Associated Press, the FDA has approved expanded use of Merck’s toxic antipsychotic drug, Saphris, for treating acute manic-depressive behavior in adults. Antipsychotics (neuroleptics) are a controversial class of drugs: Risperdal (approved in 1993), Zyprexa (1994), Seroquel . . . Continue reading →
The prescribed drugs transformed Kyle Warren from a rambunctious healthy child into a drooling, sedated, obese, “shell.” Continue reading →
"Dr. Nemeroff has become the poster child for what’s wrong with academic medicine in our country." Dr. Thomas Insell, Director of the NIMH, quietly helped him get a prized position at the University of Miami.
Any FDA-approved drug, whose manufacturer has been found by a court of law or the Department of Justice–to have illegally marketed the drug by concealing risks or incidence of adverse effects, or making unsupported claims of clinical benefit–should be denied coverage by taxpayer funded insurance programs–including Medicaid, Medicare, VeteranstAffairs. Continue reading →